Table 1.
Patients’ characteristics at time of transplantation.
| Whole Cohort | By Occurrence of dnDSA between 2 and 3 Years Post Transplant | |||||
|---|---|---|---|---|---|---|
| N | N | No dnDSA n = 207 | dnDSA n = 19 | p Value | ||
| Age (years), median (IQR) | 301 | 51.0 (40.0–60.0) | 226 | 48.8 | 42.3 | 0.04 |
| Male, n (%) | 301 | 208 (69.1) | 226 | 145 (70.0) | 15 (79.0) | 0.60 |
| Primary kidney disease | 295 | 221 | 0.42 | |||
| Vascular, n (%) | 10 (3.4) | 6 (3.0) | 0 (0.0) | |||
| Diabetics, n (%) | 24 (8.1) | 16 (7.9) | 2 (10.5) | |||
| Glomerulonephritis, n (%) | 82 (27.8) | 58 (28.7) | 9 (47.4) | |||
| Tubulo-interstitial, n (%) | 31 (10.5) | 24 (11.9) | 3 (15.8) | |||
| Hereditary (including polycystic kidney disease), n (%) | 64 (21.7) | 52 (25.7) | 2 (10.5) | |||
| Other or undetermined, n (%) | 84 (28.5) | 46 (22.8) | 3 (15.8) | |||
| Dialysis modality before transplant | 292 | 203 | 0.11 | |||
| Preemptive transplantation, n (%) | 27 (9.3) | 1 (0.5) | 0 (0.0) | |||
| Hemodialysis, n (%) | 221 (75.7) | 147 (79.5) | 18 (100.0) | |||
| Peritoneal dialysis, n (%) | 44 (15.1) | 37 (0.2) | 0 (0.0) | |||
| Number of previous graft(s) | 271 | 224 | 0.36 | |||
| 0, n (%) | 224 (82.7) | 172 (83.9) | 16 (84.2) | |||
| 1, n (%) | 41 (15.1) | 30 (14.6) | 2 (10.5) | |||
| ≥2, n (%) | 6 (2.3) | 2 (1.0) | 1 (5.3) | |||
| Sensitized patients, n (%) | 226 | 61 (27) | 226 | 0.11 | ||
| Yes | 59 (28.5) | 2 (10.5) | ||||
| No | 148 (71.5) | 17 (89.5) | ||||
| Donor age (years), mean (SD) | 278 | 49.2 (15.9) | 217 | 47.1 (15.5) | 45.8 (18.4) | 0.75 |
| Living donor, n (%) | 298 | 9 (3.0) | 225 | 6 (2.9) | 0 (0.0) | 1.00 |
| Expanded criteria donor, n (%) | 274 | 116 (42.3) | 213 | 67 (34.5) | 5 (26.3) | 0.61 |
| Number of HLA mismatches (A–B–DR) | 295 | 224 | 0.12 | |||
| 0, n (%) | 3 (1.0) | 1 (0.5) | 0 (0.0) | |||
| 1, n (%) | 10 (3.4) | 7 (3.4) | 0 (0.0) | |||
| 2, n (%) | 26 (8.8) | 14 (6.8) | 1 (5.3) | |||
| 3, n (%) | 48 (16.3) | 29 (14.1) | 4 (21.1) | |||
| 4, n (%) | 91 (30.8) | 64 (31.2) | 3 (15.8) | |||
| 5, n (%) | 85 (28.8) | 61 (29.8) | 11 (57.9) | |||
| 6, n (%) | 32 (10.8) | 29 (14.1) | 0 (0.0) | |||
| Total ischemia time (hours), median (IQR) | 269 | 15.8 (13.0–19.0) | 212 | 16.5 (6.0) | 16.2 (6.8) | 0.84 |
| Induction treatment | 276 | 206 | 0.41 | |||
| Basiliximab, n (%) | 168 (60.9) | 125 (66.1) | 9 (52.9) | |||
| rATG, n (%) | 108 (39.1) | 64 (33.9) | 8 (47.1) | |||
| Delayed graft function, n (%) | 292 | 61 (20.9) | 220 | 40 (19.8) | 5 (27.8) | 0.38 |
| Maintenance treatment at 3 months post-transplant | 296 | 219 | 0.002 | |||
| Cyclosporine | 64 (21.6) | 46 (23.0) | 11 (57.9) | |||
| Tacrolimus | 227 (76.7) | 151 (75.5) | 7 (36.8) | |||
| Without CNI | 5 (1.7) | 3 (1.5) | 1 (5.3) | |||
| Maintenance treatment at 6 months post-transplant | 294 | 219 | 0.004 | |||
| Cyclosporine | 61 (20.7) | 46 (23.0) | 9 (47.4) | |||
| Tacrolimus | 226 (76.9) | 150 (75.0)) | 8 (42.1) | |||
| Without CNI | 7 (2.4) | 4 (2.0) | 2 (10.5) | |||
| Maintenance treatment at 12 months post-transplant | 291 | 219 | 0.02 | |||
| Cyclosporine | 55 (18.9) | 42 (21.0) | 8 (42.1) | |||
| Tacrolimus | 224 (77.0) | 151 (75.5) | 9 (47.4) | |||
| Without CNI | 12 (4.1) | 7 (3.5) | 2 (10.5) | |||
| Maintenance treatment at 24 months post-transplant | 282 | 218 | 0.01 | |||
| Cyclosporine | 53 (18.8) | 41 (20.6) | 7 (36.8) | |||
| Tacrolimus | 214 (75.9) | 150 (75.4) | 9 (47.4) | |||
| Without CNI | 15 (5.3) | 8 (4.0) | 3 (15.8) | |||
| Corticosteroids at 3 months | 301 | 226 | 0.23 | |||
| Continued | 255 (84.7) | 190 (91.8) | 16 (84.2) | |||
| Discontinued | 46 (15.3) | 17 (8.2) | 3 (15.8) | |||
N: subjects with available data; IQR: Interquartile range; SD: standard deviation; HLA: Human Leucocyte Antigen; CMV: Cytomegalovirus. The bold elements correspond to the headers and differentiate the name of the variable from the categories of this variable.